BA
LXRX icon

Boston Advisors’s Lexicon Pharmaceuticals LXRX Stock Holding History

Boston Advisors’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-31,855
Closed -$524K – 657
2017
Q2 		$524K Sell
31,855
-800
-2% -$12.4K 0.01% 486
2017
Q1 		$468K Buy
32,655
+2,695
+9% +$40K 0.01% 481
2016
Q4 		$414K Buy
29,960
+7,980
+36% +$128K 0.01% 515
2016
Q3 		$397K Buy
+21,980
New +$354K 0.01% 558

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UIM
USS Investment Management London, United Kingdom $27.8B AUM 39.42% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Boston Advisors's LXRX Position: Q3 2017 in Review

Boston Advisors sold out of Lexicon Pharmaceuticals (LXRX) in Q3 2017, closing a stake of 31,855 shares — an estimated $524K sold.

Boston Advisors first reported a position in LXRX in Q3 2016 and held it in 4 quarters. The position peaked at $524K in Q2 2017. 137 funds tracked by Wall St. Rank hold LXRX as of Q3 2017.

  • Boston Advisors reported no remaining Lexicon Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Boston Advisors sold 31,855 Lexicon Pharmaceuticals shares in Q3 2017, an estimated $524K.
  • Boston Advisors first reported a position in Lexicon Pharmaceuticals in Q3 2016 and held it in 4 quarters.
  • Boston Advisors's Lexicon Pharmaceuticals position peaked at $524K in Q2 2017.
  • 137 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2017.

Based on Boston Advisors's 13F filing for Q3 2017, filed 24 Oct 2017.